182 related articles for article (PubMed ID: 34982354)
21. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
22. Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time.
Ousmen A; Conroy T; Guillemin F; Velten M; Jolly D; Mercier M; Causeret S; Cuisenier J; Graesslin O; Hamidou Z; Bonnetain F; Anota A
Health Qual Life Outcomes; 2016 Dec; 14(1):167. PubMed ID: 27914467
[TBL] [Abstract][Full Text] [Related]
23. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study.
Kvam AK; Fayers P; Wisloff F
Eur J Haematol; 2010 Apr; 84(4):345-53. PubMed ID: 20041946
[TBL] [Abstract][Full Text] [Related]
24. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals.
Pilz MJ; Gamper EM; Efficace F; Arraras JI; Nolte S; Liegl G; Rose M; Giesinger JM;
BMC Public Health; 2022 May; 22(1):1040. PubMed ID: 35610611
[TBL] [Abstract][Full Text] [Related]
25. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.
Maringwa J; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Reeve BB; Gotay C; Greimel E; Flechtner H; Cleeland CS; Schmucker-Von Koch J; Weis J; Van Den Bent MJ; Stupp R; Taphoorn MJ; Bottomley A;
Ann Oncol; 2011 Sep; 22(9):2107-2112. PubMed ID: 21324954
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
27. International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer.
Petersen MA; Aaronson NK; Conroy T; Costantini A; Giesinger JM; Hammerlid E; Holzner B; Johnson CD; Kieffer JM; van Leeuwen M; Nolte S; Ramage JK; Tomaszewski KA; Waldmann A; Young T; Zotti P; Groenvold M;
Qual Life Res; 2020 May; 29(5):1405-1417. PubMed ID: 31955374
[TBL] [Abstract][Full Text] [Related]
28. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.
Mierzynska J; Taye M; Pe M; Coens C; Martinelli F; Pogoda K; Velikova G; Bjelic-Radisic V; Cardoso F; Brain E; Ignatiadis M; Piccart M; Van Tienhoven G; Mansel R; Wildiers H; Bottomley A;
Eur J Cancer; 2020 Jan; 125():69-82. PubMed ID: 31838407
[TBL] [Abstract][Full Text] [Related]
29. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
30. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.
Nolte S; Liegl G; Petersen MA; Aaronson NK; Costantini A; Fayers PM; Groenvold M; Holzner B; Johnson CD; Kemmler G; Tomaszewski KA; Waldmann A; Young TE; Rose M;
Eur J Cancer; 2019 Jan; 107():153-163. PubMed ID: 30576971
[TBL] [Abstract][Full Text] [Related]
31. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.
Guzelant A; Goksel T; Ozkok S; Tasbakan S; Aysan T; Bottomley A
Eur J Cancer Care (Engl); 2004 May; 13(2):135-44. PubMed ID: 15115469
[TBL] [Abstract][Full Text] [Related]
32. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research.
Giesinger JM; Loth FLC; Aaronson NK; Arraras JI; Caocci G; Efficace F; Groenvold M; van Leeuwen M; Petersen MA; Ramage J; Tomaszewski KA; Young T; Holzner B;
J Clin Epidemiol; 2020 Feb; 118():1-8. PubMed ID: 31639445
[TBL] [Abstract][Full Text] [Related]
33. Updated EORTC QLQ-C30 general population norm data for Germany.
Nolte S; Waldmann A; Liegl G; Petersen MA; Groenvold M; Rose M;
Eur J Cancer; 2020 Sep; 137():161-170. PubMed ID: 32777715
[TBL] [Abstract][Full Text] [Related]
34. Reliability and validity of Amharic version of EORTC QLQ-C30 and QLQ-BR23 modules for assessing health-related quality of life among breast cancer patients in Ethiopia.
Gadisa DA; Gebremariam ET; Ali GY
Health Qual Life Outcomes; 2019 Dec; 17(1):182. PubMed ID: 31830992
[TBL] [Abstract][Full Text] [Related]
35. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler G; Holzner B; Kopp M; Dünser M; Margreiter R; Greil R; Sperner-Unterweger B
J Clin Oncol; 1999 Sep; 17(9):2932-40. PubMed ID: 10561373
[TBL] [Abstract][Full Text] [Related]
36. Identifying health-related quality of life cut-off scores that indicate the need for supportive care in young adults with cancer.
Lidington E; Giesinger JM; Janssen SHM; Tang S; Beardsworth S; Darlington AS; Starling N; Szucs Z; Gonzalez M; Sharma A; Sirohi B; van der Graaf WTA; Husson O
Qual Life Res; 2022 Sep; 31(9):2717-2727. PubMed ID: 35476170
[TBL] [Abstract][Full Text] [Related]
37. Underlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer.
Viada C; Bouza C; Fors M; Frías A; Alvarez M; García L; Wilkinson B; Rodríguez C; Crombet T; Ballesteros J
Qual Life Res; 2020 Dec; 29(12):3441-3448. PubMed ID: 33136243
[TBL] [Abstract][Full Text] [Related]
38. Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity.
Juul T; Petersen MA; Holzner B; Laurberg S; Christensen P; Grønvold M
Qual Life Res; 2014 Oct; 23(8):2183-93. PubMed ID: 24676897
[TBL] [Abstract][Full Text] [Related]
39. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain.
Giesinger JM; Kuijpers W; Young T; Tomaszewski KA; Friend E; Zabernigg A; Holzner B; Aaronson NK
Health Qual Life Outcomes; 2016 Jun; 14():87. PubMed ID: 27267486
[TBL] [Abstract][Full Text] [Related]
40. Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study.
Machingura A; Taye M; Musoro J; Ringash J; Pe M; Coens C; Martinelli F; Tu D; Basch E; Brandberg Y; Grønvold M; Eggermont A; Cardoso F; Van Meerbeeck J; van der Graaf WTA; Taphoorn M; Reijneveld JC; Soffietti R; Sloan J; Velikova G; Flechtner H; Bottomley A;
Eur J Cancer; 2022 Jul; 170():1-9. PubMed ID: 35569438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
